

when b is 1, R²⁷ is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, dialkylaminoalkyl, and carboxymethyl;

when b is 2, R²⁷ is alkylene in which a methylene group is optionally replaced by O, NH, or N-alkyl; and their thioxo analogs,

and the acid addition salts or anionic salts thereof; and

(c) at least one physiologically acceptable carrier.

Sub 103
42. The composition of claim 41 comprising a further cancerostatic or immunosuppressive agent that is not a compound of formula I.

AR
43. The composition of claim 41 where the compound(s) of formula I and the compound(s) of formula II - Vb are contained separately within the composition.

44. The composition of claim 41 where the compound(s) of formula I and the compound(s) of formula II - Vb are present in separate dosage forms, and the dosage forms are packaged together for co-administration. --


REMARKS

The Amendment

Entry of this amendment is respectfully requested. No new matter is added by the amendments, because the new claims find support in the application as filed. In particular, the new claims limit the claim dependencies and rewrite the claims in more standard US form.

Claims 32-44 are in this application, Claims 1-31 having been canceled, and Claims 32-44 having been added by this amendment. Entry of the amendment and allowance of the claims are requested.

Respectfully submitted,



Derek P. Freyberg
Attorney for Applicants
Reg. No. 29,250

Heller Ehrman White & McAuliffe LLP
275 Middlefield Road
Menlo Park CA 94025-3506
(650) 324-7014

June 11, 2001